weekly_roundup

BioTechSign Daily Catalyst Roundup - November 06, 2026

Top BioTechSign catalyst names today: EYPT, GRFS, NKTR, ARGX, NUVB, ALNY. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 6, 2026

Daily Biotech Catalyst Digest: November 06, 2026

EYPT leads the current BioTechSign screen at 84.8/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
EYPTEyePoint, Inc.84.8Aclinical activity 100%, short interest 70%, dilution risk 43%
GRFSGrifols SA74.8Bpublication signal 100%, clinical activity 100%, dilution risk 19%
NKTRNektar Therapeutics74.0Bshort interest 90%, clinical activity 75%, dilution risk 65%
ARGXargenx SE74.0Bpublication signal 100%, clinical activity 100%, dilution risk 15%
NUVBNuvation Bio73.4Bclinical activity 88%, PDUFA timing 75%, short interest 70%
ALNYAlnylam Pharmaceuticals72.9Bpublication signal 100%, clinical activity 100%, dilution risk 10%

Recent Grade-Change Queue

  • IBRX (ImmunityBio, Inc.) currently grades B with a 70.0/100 catalyst score. Main inputs: clinical activity 100%, short interest 90%, PDUFA timing 55%.
  • GLUE (Monte Rosa Therapeutics) currently grades D with a 42.1/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 48%.
  • CADL (Candel Therapeutics, Inc.) currently grades F with a 26.7/100 catalyst score. Main inputs: short interest 70%, clinical activity 38%, dilution risk 27%.
  • ALNY (Alnylam Pharmaceuticals) currently grades B with a 72.9/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 10%.
  • DYN (Dyne Therapeutics) currently grades D with a 42.2/100 catalyst score. Main inputs: publication signal 100%, clinical activity 58%, PDUFA timing 55%.
  • URGN (UroGen Pharma Ltd.) currently grades F with a 27.8/100 catalyst score. Main inputs: clinical activity 54%, short interest 50%, dilution risk 45%.
  • FATE (Fate Therapeutics) currently grades F with a 25.5/100 catalyst score. Main inputs: publication signal 100%, short interest 50%, dilution risk 35%.
  • COGT (Cogent Biosciences) currently grades B with a 66.9/100 catalyst score. Main inputs: publication signal 100%, PDUFA timing 90%, short interest 50%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.